Loading...
Market
Private-equity backed IRB board sanctioned by Dec 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from regulatory bodies or news reports
Story
Alzheimer's Drugmakers Withheld Genetic Risk Information from Trial Participants and Families
Oct 24, 2024, 01:44 AM
Alzheimer's drugmakers did not inform trial participants and their families that genetic tests showed they were at high risk for brain bleeds. Participants were required to sign consent forms acknowledging the risk of brain injuries due to certain genetic profiles and that they would be tested, but the results were not disclosed to them. This has raised ethical concerns and questions about the role of private-equity backed IRB boards in the trials. One observer noted, 'It’s not even a matter of ethics, it’s a matter of common sense.'
View original story
Similar markets
Yes • 50%
No • 50%
Executive from Teledyne Brown Engineering • 25%
Executive from BRINC Drones • 25%
Executive from Shield AI • 25%
Executive from Kratos • 25%
Yes • 50%
No • 50%
No wrongdoing found • 25%
Regulations revised • 25%
Penalties imposed on Blackstone • 25%
Involvement of Dhaval Buch confirmed • 25%
Approved • 33%
Rejected • 33%
Pending • 34%
SAB 121 is rescinded • 25%
SAB 121 is modified • 25%
SAB 121 remains unchanged • 25%
Other • 25%
Yes • 50%
No • 50%
